Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Apr 20, 2015Results Published in the Journal of American College of CardiologyToday the Journal of the American College of Cardiology published data confirming the long-term safety and efficacy of the Boston Scientific Corporation (NYSE: BSX) S-ICD System™ (subcutaneous...
Apr 16, 2015Boston Scientific Corporation (NYSE: BSX) is taking a new approach to evaluate the performance of the Vessix™ Renal Denervation System, initiating a study with a novel design to isolate the...
Apr 14, 2015Companies Plan to Accelerate Physician Training and Expand Utilization of Less-Invasive Endoscopy Technologies in ChinaBoston Scientific Corporation (NYSE: BSX), a leading global medical device company, announced the signing of a strategic alliance with Frankenman Medical Equipment Company, a recognized leader...
- Apr 1, 2015
Boston Scientific Corporation (NYSE: BSX) announces that it has signed a definitive agreement to acquire Xlumena, Inc., a venture-backed medical device company that develops, manufactures and...
Apr 1, 2015Boston Scientific Corporation (NYSE: BSX) will webcast a conference call on Tuesday, April 28, 2015 at 8 a.m. ET to review financial results and business highlights for the first quarter 2015. The...
Mar 24, 2015Novel Stroke Risk Reduction Option for Indicated Patients with Atrial FibrillationThis week, four patients in the United States received the first implants of the Boston Scientific Corporation (NYSE: BSX) WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device. The WATCHMAN...
Mar 17, 2015Innovative device offers first-line treatment for patients at risk of sudden cardiac arrestBoston Scientific Corporation (NYSE: BSX) has received FDA and CE Mark approval of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System. The EMBLEM S-ICD System is a treatment...
Mar 13, 2015First-Of-Its-Kind Alternative to Long-Term Warfarin Therapy for Stroke Risk Reduction in Patients with Non-Valvular Atrial FibrillationBoston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the WATCHMAN Left Atrial Appendage Closure Device. The WATCHMAN Device offers a new...
Mar 3, 2015Boston Scientific Corporation (NYSE: BSX) announces the election of Charles J. Dockendorff and Stephen P. MacMillan to its board of directors, effective April 1, 2015. Two current members of the...
Mar 2, 2015Combined Business to Advance Patient Care with Leading Solutions Across Major Urology CategoriesBoston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement with Endo International plc (NASDAQ: ENDP) (TSX: ENL) to acquire the American Medical...